<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00865540</url>
  </required_header>
  <id_info>
    <org_study_id>OMB NO:0925-0586</org_study_id>
    <nct_id>NCT00865540</nct_id>
  </id_info>
  <brief_title>Effect of Anti-inflammatory Topical Prednisolone, Nepafenac and Ketorolac in Intra-operative Mydriasis in Facetectomies</brief_title>
  <official_title>Effect of Anti-inflammatory Topical Prednisolone Acetate 1%, Nepafenac of 0.1% and Ketorolac Tromethamine 0.4% in Intra-operative Mydriasis in Facetectomies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinica Oftamologica Zona Sul</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clinica Oftamologica Zona Sul</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to compare the effect of preoperative use of
      anti-inflammatory topical prednisolone acetate 1%, nepafenac 0.1% and ketorolac tromethamine
      0.4% of, plus a placebo, in maintaining the intra-operative mydriasis in extraction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Will be conducted with a randomized clinical trial volunteers with indication of extraction
      in Recife, Brazil. The surgical technique is employed phacoemulsification with implantation
      of intraocular lens. Digital photos are taken of the eye at the beginning and end of surgery
      and with them will be digitally determined the relationship between the corneal area and
      pupillary area. Each volunteer will be drawn to one of four groups of study (group 1,
      prednisolone acetate 1%, group 2, of ketorolac tromethamine 0.4%, 0.1% nepafenac group 3 and
      group 4, placebo). For the volunteers randomly selected for each group will be prescribed
      medication in its presentation as eye drops (Prednisolone acetate 1%, Pred Fort ®, Allergan
      ®; of ketorolac tromethamine 0.4%, incite l ®, Allergan ®; Nepafenac 0.1%, Nevanac ® Alcon ®
      and 0.5% methylcellulose, Fresh Tears ®, Allergan ®), 01 drop every 8 hours for 48 hours
      before surgery. For all volunteers will also be prescribed gatifloxacin (Zymar ®), 01 drop
      every 8 hours starting 48 hours before surgery. Was scheduled a minimum sample of 60
      volunteers (15 per group).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2009</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">August 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pupil size</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>prednisolone acetate 1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one drop every 8h two days before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ketorolac tromethamine 0.4%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one drop every 8h two days before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nepafenac 0.1%</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>one drop every 8h two days before surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>one drop every 8h two days before surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>prednisolone acetate 1%</intervention_name>
    <description>1 drop every 8h two days before surgery</description>
    <arm_group_label>prednisolone acetate 1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ketorolac tromethamine 0.4%</intervention_name>
    <description>1 drop every 8h two days before surgery</description>
    <arm_group_label>ketorolac tromethamine 0.4%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nepafenac 0.1%</intervention_name>
    <description>1 drop every 8h two days before surgery</description>
    <arm_group_label>nepafenac 0.1%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylcellulose 0.5%</intervention_name>
    <description>1 drop every 8h two days before surgery</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Carriers of senile cataract (&gt; 50 years of age) with indication for cataract
             extraction with implantation of intraocular lens, with local anesthesia

        Exclusion Criteria:

          -  Diabetic

          -  Using systemic anti-hormonal and non-hormonal

          -  Using topical ocular medication (including anti-glaucomatous)

          -  Individuals with congenital ocular abnormalities and cases in which there is
             intra-operative complications (hernia or trauma in the iris, posterior capsule rupture
             or zônula and prolonged phacoemulsification time of ≥ 1 minute).

          -  Volunteers with incipient nuclear cataract (density 1) or advanced (density 4) by the
             LOCS II classification (density of nuclear cataract ranked 1 to 4 (Chalk et al, 1989)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandre P Costa, Pinto</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clínica Oftalmológica Zona Sul</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clínica Oftalmológica Zona Sul</name>
      <address>
        <city>Recife</city>
        <state>Pernambuco</state>
        <zip>51020-031</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 18, 2009</study_first_submitted>
  <study_first_submitted_qc>March 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2009</study_first_posted>
  <last_update_submitted>May 23, 2011</last_update_submitted>
  <last_update_submitted_qc>May 23, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 24, 2011</last_update_posted>
  <responsible_party>
    <name_title>Alexandre Paashaus da Costa Pinto</name_title>
    <organization>Clínica Oftalmológica Zona Sul</organization>
  </responsible_party>
  <keyword>cataract</keyword>
  <keyword>pupillary dilation</keyword>
  <keyword>anti-inflammatory</keyword>
  <keyword>therapeutic use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Mydriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Nepafenac</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Ketorolac</mesh_term>
    <mesh_term>Ketorolac Tromethamine</mesh_term>
    <mesh_term>Anti-Inflammatory Agents</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

